Prof William Hope FRACP, FRCPA, PhD

Dame Sally Davies Chair of AMR Research, Director of Centre of Excellence in Infectious Diseases Research Molecular and Clinical Pharmacology

    Research

    Research Interest 1

    The research themes of the Antimicrobial Pharmacodynamics and Therapeutics Laboratory are as follows:

    1. Development of New Antimicrobial Agents
    2. Repurposing and Optimisation
    3. Antimicrobials for Neonates and Children
    4. Antimicrobials for Neglected Tropical Diseases
    5. Individualisation of Antimicrobial Therapy


    Details of each research theme can be found at Antimicrobial Pharmacodynamics and Therapeutics

    Research Grants

    Pharmacodynamics of Amphotericin B Cochleates for Cryptococcal Meningitis

    MATINAS BIOPHARMA NANOTECHNOLOGIES, INC (USA)

    April 2017 - July 2017

    Pharmacodynamics of Tebipenem

    SPERO OPCO INC (USA)

    August 2016 - July 2018

    High Dose AMBISOME© on a Fluconazole Backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Randomized Controlled Non-inferiority Trial (AMBITION)

    EDCTP (NETHERLANDS)

    January 2017 - December 2020

    Pharamcodyanmics of new antimicrobial agents for neonatal meningitis

    FOOD AND DRUG ADMINISTATION (USA)

    September 2016 - September 2019

    Assessment of tebipenem in the hollow fibre

    SPERO OPCO INC (USA)

    August 2016 - July 2018

    ADAPT

    DEPARTMENT OF HEALTH (UK) (NIHR)

    April 2019 - March 2021

    Pharmacodynamics of SPR206

    SPERO OPCO INC (USA)

    June 2018 - July 2020

    Pharmacodynamics of Meropenem and metallobetalactmase inhibitors against NDM producing Gram Negatives

    ANTABIO (FRANCE)

    September 2017 - February 2018

    Pharmacodynamics of Antimicrobial Combinations for Neonatal Sepsis in Low-To-Middle Income Countries

    DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI) (SWITZERLAND)

    November 2018 - November 2019

    AAI101 and Cefepime in Epithelial Lining Fluid and Plasma in Healthy Volunteers REC

    ALLECRA THERAPEUTICS GMBH (GERMANY)

    January 2018 - September 2022

    PK-PD analyses of cefepime and AAI101 against MDR enterobacteriaceae

    ALLECRA THERAPEUTICS GMBH (GERMANY)

    October 2017 - October 2018

    Unlocking the potential of teixobactin analogues to target multi-drug resistant bacteria (TBC)

    INNOVATE UK (UK)

    April 2019 - March 2020

    Pharmacokinetic-Pharmacodynamic analyses of novel metallo-betalactmase inhibitors in multidrug resistant Gram negative infections

    ANTABIO (FRANCE)

    May 2018 - October 2019

    Assessment of the PKPD of BWC0977

    BUGWORKS RESEARCH INDIA PVT. LTD. (INDIA)

    May 2019 - May 2021

    Spatially-resolved PKPD modelling for optimised treatment of central nervous system infection due to Mycobacterium tuberculosis

    MEDICAL RESEARCH COUNCIL (MRC)

    August 2016 - July 2019

    Rational Design, Synthesis and Biological Evaluation of Benzimidazoles Towards a Novel Therapy Selectively Targeting C. neoformans beta-tubulin

    MEDICAL RESEARCH COUNCIL (MRC)

    July 2016 - December 2019

    Centre for Antimicrobial Pharmacodynamics

    INNOVATE UK (UK)

    January 2017 - March 2017

    Pharmacodynamics of Novel Potentiators Against Multidrug Resistant Gram Negative Infections

    SPERO OPCO INC (USA)

    August 2016 - July 2017

    Combatting Bacterial Resistance in Europe COMBACTE-MAGNET

    AICURIS GMBH (GERMANY), EUROPEAN COMMISSION

    January 2015 - December 2021

    Pharmacodynamics of Novel Antifungal Agents Against Aspergillus fumigatus

    F2G LTD (UK)

    May 2013 - June 2016

    Pharmacodynamics of Voricamozole against fusarium SPP and scedosporium apiospermum: Identification of in vitro suscepibility breakpoints and targets for theraputic drug monitoring

    EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES (SWITZERLAND)

    June 2013 - May 2014

    Preserving old antibiotics for the future : assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for off‐patent antibiotics

    EUROPEAN COMMISSION

    April 2013 - November 2016

    Towards complete sustained release nanoformulations of NRTI based regimens

    NATIONAL INSTITUTES OF HEALTH (NIH) (USA)

    July 2014 - June 2019

    Generating Micafungin amd Isavuconazole MICs Versus Candida spp. using EUCAST Methodology

    ASTELLAS PHARMA GLOBAL DEVELOPMENT (USA)

    August 2012 - July 2013

    A Control Theory Approach for Individualisation of Antifungal dosing in Immunocomprised Patients

    DEPARTMENT OF HEALTH (UK) (NIHR)

    June 2012 - September 2016

    Treatment of late onset bacterial sepsis caused by Vancomycin susceptible bacteria in neonates and infants aged under three months (NeoVanc)

    EUROPEAN COMMISSION

    February 2014 - July 2020

    Cryptococcal meningitis: addressing an urgent global health problem using a translational pharmacological approach

    MEDICAL RESEARCH COUNCIL (MRC)

    December 2012 - February 2015